Type 2 Diabetes Mellitus
Conditions
Brief summary
This study aims to assess the impact of 24-week treatment of dapagliflozin in type 2 DM(diabetes mellitus) patients on diastolic dysfunction. Primary endpoint is assessing the impact of 24-week treatment of dapagliflozin in type 2 DM patients on subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography. Secondary endpoint is assessing the impact of 24-week treatment of dapagliflozin in type 2 DM patients on functional capacity, he impact of 24-week treatment of dapagliflozin in type 2 DM patients at resting diastolic function. This is single-center, randomized, double-blind, placebo-controlled, parallel-arm intervention study. This study is planned to evaluate the impact of dapagliflozin on diastolic dysfunction assessed. The dose of dapagliflozin will be 10 mg as approved. For assessment of diastolic dysfunction, supine bicycle stress exercise echocardiography was performed, and changes in diastolic functional reserve, VO2max, exercise time, and maximal exercise capacity were assessed before and after treatment. This study will be randomized, double blind, placebo controlled, to minimize the risk of bias.
Interventions
DRUGDapagliflozin 10mg
DRUGPlacebo 10mg
Matching placebo for dapagliflozin 10 mg
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Female and male aged 19\ 75 years * Type 2 DM and had not reached adequate glycemic control with a stable dose of metformin, sulfonylurea, or both drugs before screening * HbA1c 7.0% \ 10% at screening (Patients who take metformin only: HbA1C 6.5-10%) * Patients with ≥ grade 1 diastolic function (relaxation abnormality) at resting echocardiography * Patients provided with the written, informed consent to participate in this study
Exclusion criteria
* Type 1 DM (Fasting c-peptide ≤ 0.78ng/dL(or 0.26 nM/L)), secondary diabetes, gestational diabetes * History of diabetic ketoacidosis, hyperglycemic hyperosmolar status * Estimated glomerular filtration rate \< 60 mL/min/1.73m2 * History of chronic cystitis or recurrent urinary tract infection * Currently on loop diuretics * Currently on medication known to affect glucose metabolism (e.g. corticosteroids, immunosuppressants) * Abnormal liver function (AST/ALT \> x3 upper normal limit) * On weight loss program or taking weight loss medication * LV ejection fraction \< 50% at resting echocardiography * Uncontrolled hypertension (systolic blood pressure \>200mmHg and/or diastolic blood pressure \>110mmHg) * History of acute myocardial infarction, unstable angina, coronary artery bypass graft or stroke within 6 months * Inducible ECG abnormalities at exercise * Cardiomyopathy, significant valvular heart disease, or a significant arrhythmia * Patients who cannot perform supine bicycle stress echocardiography * Pregnant or lactating women * Subjects who the investigator deems inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography | 24-week |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the impact of dapagliflozin on resting diastolic function | 24-week | Diastolic function measured by LV mass index, Grade of diastolic function, Ea velocity, Left atrial volume index |
| the impact of dapagliflozin on patients' functional capacity | 24-week | functional capacity measured by maximum oxygen uptake (VO2max), Exercise time, Maximum exercise capacity (METs) |
Countries
South Korea
Outcome results
None listed